文献速递糖尿病肥胖与代谢综合征

新发非酒精性脂肪性肝病及纤维化进展与慢性肾病发病风险相关

New Nonalcoholic Fatty Liver Disease and Fibrosis Progression Associate With the Risk of Incident Chronic Kidney Disease.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该社区前瞻性研究纳入2010年基线无慢性肾病、年龄40岁及以上者4042人,平均随访4.4年。在校正糖尿病、高血压、肥胖演变及基线水平等混杂因素后,新发非酒精性脂肪性肝病(NAFLD)与慢性肾病(CKD)发病风险升高相关(OR=1.44;95%CI,1.003-2.06;P=0.048);持续NAFLD者中纤维化评分由低升至中/高与CKD发病风险升高相关(OR=2.82;95%CI,1.22-6.56;P=0.016)。

要点

  • 新发NAFLD与CKD发病风险升高相关(OR=1.44;95%CI,1.003-2.06;P=0.048)。
  • NAFLD缓解与持续NAFLD之间CKD发病风险无显著差异。
  • 持续NAFLD者纤维化由低升至中/高NFS,CKD风险升高(OR=2.82;95%CI,1.22-6.56;P=0.016)。

核心结论

  • NAFLD发生及纤维化进展与CKD发病风险升高相关。

研究设计与样本

  • 社区为基础的前瞻性研究,纳入2010年基线无CKD、年龄40岁及以上参与者4042人,平均随访4.4年。
  • NAFLD以超声诊断,纤维化分期与进展采用NAFLD纤维化评分(NFS)评估,CKD以估算肾小球滤过率或尿白蛋白与肌酐比值定义。
  • 所有测量均在基线和随访检查时进行。

主要发现

  • 与无NAFLD相比,新发NAFLD与CKD发病风险升高相关(OR=1.44;95%CI,1.003-2.06;P=0.048),校正了糖尿病、高血压、肥胖的演变及基线水平等混杂因素。
  • NAFLD缓解与持续NAFLD之间CKD发病风险无显著差异。
  • 在持续NAFLD组的534名参与者中,纤维化由低NFS进展至中或高NFS与CKD发病风险显著升高相关(OR=2.82;95%CI,1.22-6.56;P=0.016)。

临床怎么用

  • 在内分泌代谢门诊评估NAFLD患者时,应关注其CKD发病风险,尤其是新发NAFLD及纤维化进展者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Little is known about the link between nonalcoholic fatty liver disease (NAFLD) evolution and incident chronic kidney disease (CKD). OBJECTIVE: We aim to assess the associations of NALFD status changes and NAFLD fibrosis progression with the risk of incident CKD. METHODS: We conducted a community-based prospective study that included participants aged 40 years or older and free of CKD at baseline in 2010, with follow-up evaluations after a mean of 4.4 years. NAFLD was diagnosed by ultrasonography and NAFLD fibrosis score (NFS) was used to evaluate fibrosis stage and progression. CKD was defined by estimated glomerular filtration rate or urine albumin-to-creatinine ratio. All the measurements were performed at baseline and follow-up examination. RESULTS: Among 4042 participants with 4 NAFLD status change groups, incident NAFLD was associated with an increased risk of incident CKD (odds ratio [OR] = 1.44; 95% CI, 1.003-2.06; P = 0.048) compared with non-NAFLD after adjustments for the confounders, including evolution of diabetes, hypertension, and obesity, in addition to the baseline levels. However, the risk of incident CKD was not significantly different between NAFLD resolution and persistent NAFLD. Among 534 participants in the persistent NAFLD group, fibrosis progression from low NFS to intermediate or high NFS was associated with a significantly increased risk of incident CKD compared with stable fibrosis in low NFS (OR = 2.82; 95% CI, 1.22-6.56; P = 0.016). CONCLUSION: NAFLD development and fibrosis progression are associated with increased risk of incident CKD.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Zuo G, Xuan L, Xin Z, et al. New Nonalcoholic Fatty Liver Disease and Fibrosis Progression Associate With the Risk of Incident Chronic Kidney Disease. J Clin Endocrinol Metab. 2021. PMID: 34125886. doi:10.1210/clinem/dgab425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。